Dupilumab therapy in Sézary syndrome misdiagnosed as atopic dermatitis: A case report

2020 ◽  
Vol 47 (10) ◽  
Author(s):  
Naoka Umemoto ◽  
Toshio Demitsu ◽  
Kaoru Otaki ◽  
Takanao Matsumoto ◽  
Maya Takazawa ◽  
...  
2021 ◽  
Vol 156 ◽  
pp. S51-S52
Author(s):  
Florent Amatore ◽  
Emily Connell ◽  
Marie Aymonier ◽  
Caroline Gaudy-Marqueste ◽  
Marie-Aleth Richard

Skin Cancer ◽  
2016 ◽  
Vol 31 (2) ◽  
pp. 179-183
Author(s):  
Soichiro WATANABE ◽  
Yohei IWATA ◽  
Sigeki NUMATA ◽  
Aki ANDO ◽  
Tukane KOBAYASHI ◽  
...  

2018 ◽  
Vol 46 (1) ◽  
pp. 61-64 ◽  
Author(s):  
Hiroaki Kamijo ◽  
Tomomitsu Miyagaki ◽  
Yuta Norimatsu ◽  
Naomi Shishido-Takahashi ◽  
Ai Kuzumi ◽  
...  

2019 ◽  
Vol 37 (2) ◽  
pp. 202-204
Author(s):  
Laura Nanni ◽  
Alice Morigi ◽  
Beatrice Casadei ◽  
Alessandro Broccoli ◽  
Vittorio Stefoni ◽  
...  

2016 ◽  
Vol 2016 ◽  
pp. 1-15 ◽  
Author(s):  
Ieva Saulite ◽  
Wolfram Hoetzenecker ◽  
Stephan Weidinger ◽  
Antonio Cozzio ◽  
Emmanuella Guenova ◽  
...  

Sézary syndrome (SS), an aggressive form of erythrodermic pruritic cutaneous T cell lymphoma (CTCL), from an immunological perspective characterized by increased Th2 cytokine levels, elevated serum IgE and impaired cellular immunity. Not only the clinical appearance but also the hallmark immunological characteristics of SS often share striking similarities with acute flares of atopic dermatitis (AD), a common benign chronic inflammatory skin disease. Given the overlap of several immunological features, the application of similar or even identical therapeutic approaches in certain stages of both diseases may come into consideration. The aim of this review is to compare currently accepted immunological aspects and possible therapeutic targets in AD and SS.


Dermatology ◽  
2007 ◽  
Vol 216 (1) ◽  
pp. 68-75 ◽  
Author(s):  
Syrus Karsai ◽  
J. Steve Hou ◽  
Gladys Telang ◽  
Gary R. Kantor ◽  
Peter C. Nowell ◽  
...  

2020 ◽  
Vol 10 (1) ◽  
Author(s):  
Denis Miyashiro ◽  
José Antonio Sanches

Abstract Erythroderma is characterized by erythema and scaling affecting more than 80% of the body surface area. It is potentially life-threatening, and diagnosis of the underlying disease is a challenge. Despite laboratory improvements, many cases remain idiopathic. We aimed to analyze clinical and laboratory findings of 309 erythrodermic patients to find clues to the etiologic diagnosis. We performed a prospective study at the University of São Paulo Medical School, from 2007 to 2018, with patients with acquired erythroderma. Clinical, laboratory, histology, and molecular biology data were collected. The median age at diagnosis was 57 years, with a male-to-female ratio of 2.2. Eczema was the most frequent etiology (20.7%), followed by psoriasis (16.8%), Sézary syndrome (12.3%), drug eruption (12.3%), atopic dermatitis (8.7%), and mycosis fungoides (5.5%). Other diagnoses (6.8%) included pemphigus foliaceous, paraneoplastic erythroderma, adult T-cell leukemia/lymphoma, dermatomyositis, pityriasis rubra pilaris, lichen planus, bullous pemphigoid, and leprosy. In 52 patients (16.8%), it was not possible to elucidate erythroderma etiology. Atopic dermatitis developed erythroderma at an earlier age (median 25 years; P = 0.0001). Acute onset was associated with drug reactions and atopic dermatitis (median time from erythroderma to diagnosis of 1 and 1.5 months, respectively; P = 0.0001). Higher immunoglobulin E levels were observed in atopic dermatitis (median 24,600 U/L; P = 0.0001). Histopathology was helpful and was consistent with the final diagnosis in 72.4%. Monoclonal T-cell proliferation in the skin was observed in mycosis fungoides (33.3%) and Sézary syndrome (90.9%). At the last assessment, 211 patients (69.3%) were alive with disease, 65 (21.7%) were alive without disease, and 27 (9.1%) died with active disease. Erythroderma is a challenging syndrome with a difficult diagnostic approach. Younger age and higher immunoglobulin E levels are associated with atopic dermatitis; acute onset is observed in drug eruptions and atopic dermatitis. Histopathology and molecular biology tests are essential tools in the investigation of erythroderma.


Author(s):  
A Ganfornina Andrades ◽  
C Rodriguez Moreta ◽  
M Corrales Paz ◽  
I Lomares Manzano ◽  
MJ Martinez Bautista

Sign in / Sign up

Export Citation Format

Share Document